Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies

医学 苯拉唑马布 安慰剂 恶化 慢性阻塞性肺病 内科学 肺功能测试 哮喘 嗜酸性粒细胞 病理 美波利祖马布 替代医学
作者
Gerard J. Criner,Bartolomé R. Celli,Dave Singh,Àlvar Agustí,Alberto Papi,Maria Jison,Natalya Makulova,Vivian H. Shih,Laura Brooks,Peter Barker,Ubaldo J. Martin,Paul Newbold
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:8 (2): 158-170 被引量:114
标识
DOI:10.1016/s2213-2600(19)30338-8
摘要

Background Benralizumab did not significantly reduce exacerbations compared with placebo in the phase 3 GALATHEA and TERRANOVA trials of benralizumab for patients with chronic obstructive pulmonary disease (COPD). We aimed to identify clinical and physiological characteristics of patients with COPD that could help to identify people who are likely to have the greatest treatment effect with benralizumab. Methods We analysed individual study and pooled results from GALATHEA and TERRANOVA. At study enrolment, patients from GALATHEA and TERRANOVA were aged 40–85 years, had moderate to very severe airflow limitation, had elevated blood eosinophil counts, and at least two exacerbations or one severe exacerbation in the previous year despite dual inhaled therapy (inhaled corticosteroids plus long-acting β2-agonists or long-acting β2-agonists plus long-acting muscarinic antagonists) or triple inhaled therapy (inhaled corticosteroids plus long-acting β2-agonists plus long-acting muscarinic antagonists). We analysed data for 3910 patients who received benralizumab (30 mg or 100 mg subcutaneously every 8 weeks; first three doses every 4 weeks) or placebo with dual or triple therapy to identify factors consistently associated with annual exacerbation rate reduction. We evaluated the annual exacerbation rate for benralizumab versus placebo as the primary endpoint. GALATHEA and TERRANOVA are registered with ClinicalTrials.gov, NCT02138916 and NCT02155660, respectively. Findings For 2665 patients with elevated blood eosinophil counts, treatment effect with benralizumab every 8 weeks at 100 mg, but not at 30 mg, occurred for patients with a history of more frequent exacerbations, poorer baseline lung function, or greater baseline lung function improvement with short-acting bronchodilators. Patients with baseline blood eosinophil counts of 220 cells per μL or greater with: three or more exacerbations in the previous year receiving benralizumab every 8 weeks versus placebo, had rate ratios (RRs) of 0·69 (95% CI 0·56–0·83) for 100 mg and 0·86 (0·71–1·04) for 30 mg; postbronchodilator FEV1 of less than 40% had RRs of 0·76 (0·64–0·91) for 100 mg and 0·90 (0·76–1·06) for 30 mg; and postbronchodilator response of at least 15% had RRs of 0·67 (0·54–0·83) for 100 mg and 0·87 (0·71–1·07) for 30 mg. When combined factors were examined, patients with elevated baseline blood eosinophil counts, with three or more exacerbations in the previous year, and who were receiving triple therapy were identified as likely to benefit from benralizumab 100 mg every 8 weeks versus placebo (RR 0·70 [95% CI 0·56–0·88]). Benralizumab 30 mg every 8 weeks did not benefit patients meeting these criteria compared with placebo (RR 0·99 [95% CI 0·79–1·23]). Interpretation Elevated blood eosinophil counts combined with clinical characteristics identified a subpopulation of patients with COPD who had reductions in exacerbations with benralizumab treatment. These hypothesis-generating analyses identified the potential efficacy of benralizumab 100 mg for this subpopulation. These findings require prospective evaluation in clinical trials. Funding AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
至拙完成签到,获得积分10
刚刚
cyj完成签到,获得积分10
刚刚
MR_Z完成签到,获得积分10
刚刚
linovn完成签到,获得积分10
刚刚
明亮雨真发布了新的文献求助30
1秒前
强小强努力努力完成签到,获得积分10
1秒前
1秒前
xokey发布了新的文献求助10
1秒前
完美世界的应助被777采纳,获得10
1秒前
懵懂的芒果完成签到,获得积分10
1秒前
华仔的应助被子画三心采纳,获得10
1秒前
2秒前
求学的鱼崽崽的应助被Ace采纳,获得10
2秒前
大方飞瑶完成签到 ,获得积分10
2秒前
蒲公英完成签到,获得积分10
2秒前
逸一时误一世完成签到,获得积分10
2秒前
whm发布了新的文献求助30
2秒前
陈少华完成签到 ,获得积分10
3秒前
3秒前
null的应助被自知则知之采纳,获得10
3秒前
3秒前
千与千寻476300完成签到 ,获得积分10
3秒前
3秒前
kkk完成签到,获得积分10
3秒前
宇宙的中心完成签到,获得积分10
3秒前
hhh完成签到 ,获得积分10
3秒前
yan完成签到,获得积分10
3秒前
3秒前
hu完成签到,获得积分10
4秒前
Shrb1ng完成签到,获得积分10
4秒前
4秒前
4秒前
juju完成签到,获得积分10
5秒前
5秒前
5秒前
科研q完成签到,获得积分10
5秒前
canter2完成签到 ,获得积分10
5秒前
传奇3的应助被无芷采纳,获得10
5秒前
willow完成签到,获得积分10
5秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159542
求助须知:如何正确求助?哪些是违规求助? 9555044
关于积分的说明 21724263
捐赠科研通 7749434
什么是DOI,文献DOI怎么找? 3427246
关于科研通互助平台的介绍 2552263
邀请新用户注册赠送积分活动 2471618